Antibody-drug conjugates (ADCs) have emerged as an important class of targeted therapeutics, combining the molecular recognition of an antibody with the potency of a cytotoxic payload. Their development, however, requires substantially more than simply combining an antibody and a small molecule. An ADC development program must consider payload and linker chemistry, antibody characteristics, conjugation chemistry, drug-to-antibody ratio (DAR), process control, analytical characterization, stability and containment requirements. Shilpa's integrated capabilities bring together expertise across high-potency APIs, payloads, linkers, antibodies and bioconjugation. Its published ADC platform describes a multi-client bioconjugation suite with 200 L single-use bioconjugation reactors, lyophilization capability and dedicated development laboratories for process development, analytical characterization and scale-up.
A successful ADC process generally involves four interconnected areas: payload development, linker development, antibody production, and bioconjugation and purification. The quality of the final ADC depends on controlling each of these stages and ensuring that the resulting conjugate has the required structural, chemical and biological characteristics.
ADC payloads can be highly potent. Consequently, containment and occupational-exposure controls are critical during development and manufacturing. Shilpa Pharma describes dedicated high-containment HPAPI infrastructure covering OEL Bands 1–5, along with dedicated cytotoxic manufacturing blocks and analytical support.
ADC manufacturing increasingly benefits from an integrated CDMO model where payload, linker, antibody and conjugation capabilities can be coordinated within a controlled development framework. Such integration can simplify technology transfer, reduce interfaces between suppliers and support a more efficient path from early development to clinical and commercial manufacturing.
